EFSA health claim opinion

EFSA rejects probiotic “heart cheese” health claim

By Shane Starling

- Last updated on GMT

EFSA rejects 38-publication strong dossier for probiotic heart health cheese
EFSA rejects 38-publication strong dossier for probiotic heart health cheese

Related tags: Blood pressure

The European Food Safety Authority (EFSA) has rejected an article 13.5 claim that sought to link a probiotic cheese called Harmony with heart health benefits.

EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) found Estonian firm Piimandusühistu E-Piim’s dossier that contained 38 publications did not substantiate the proposed claim that read:

Regular consumption (at least 3 weeks) of 50 g/day Südamejuust (Heart cheese) of Harmony brand comprising probiotic Lactobacillus plantarum TENSIA helps to maintain the cardio-vascular system/heart health through reduction of blood pressure.”

The NDA said of four submitted, proprietary, unpublished intervention studies investigating the effects of the strain L. plantarum ​(Tensia) on blood pressure, three were uncontrolled and therefore not permissible as evidence.

The fourth was controlled – a randomised, double-blind, placebo-controlled, cross-over human intervention study – but the NDA said, “no significant differences in systolic or diastolic blood pressure changes were observed between the intervention and control groups during the study.”

It added: Post-hoc analyses were carried out by dividing the study population according to systolic blood pressure values at baseline. The Panel notes that these post-hoc analyses were not pre-planned and considers that no conclusions can be drawn from these analyses for the scientific substantiation of the claim.”

“In weighing the evidence, the Panel took into account that the only randomised, placebo-controlled human intervention study provided did not show an effect of consumption of L. plantarum TENSIAin Edam-type cheese on blood pressure.”

The 38 submitted publications included​guidelines, EFSA opinions, reports, narrative reviews, theses, human studies and ex vivo/in vitro ​mechanistic studies but the NDA said none of them, “addressed the effects of L. plantarum TENSIA”.

It also noted that in vitro ​information​about the functional properties of L. plantarum ​TENSIA (available in two patents) to produce angiotensin-converting enzyme (ACE) inhibitors via, “proteolytic activity in the cheese environment during maturation”​ did not, “predict an effect of L. plantarum TENSIAon blood pressure in vivo in humans.”

The NDA opinion can be found here.

Related news

Show more

Related products

show more

Health, Wellness and Innovation made easy

Health, Wellness and Innovation made easy

Univar Solutions | 16-May-2022 | Product Brochure

Tata Fossence®, a short chain FOS, is a potent prebiotic and dietary fibre derived from fermented cane sugar that selectively enhances the beneficial microbiota...

Clinically supported probiotics and postbiotics.

Clinically supported probiotics and postbiotics.

ADM | 26-Apr-2022 | Product Presentation

Today’s consumers know the importance of metabolic health and the role that the gut microbiome plays within it. After extensive research, ADM has selected...

Mediterranean Nutraceutical products

Mediterranean Nutraceutical products

Esserre Pharma | 19-Apr-2022 | Product Brochure

From the best Mediterranean ingredients to effective and safe finished products, Esserre Pharma researches and develops unique formulations.

Trending solutions for immunity beverages

Trending solutions for immunity beverages

Prinova Europe Limited | 12-Apr-2022 | Technical / White Paper

One of the effects of COVID-19 has been to increase consumer interest in beverages with functional benefits, particularly for immune health.

Related suppliers

Follow us

Products

View more

Webinars